SAR446523
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for SAR446523, covering 2026-03-25 to 2026-03-25. Get the full timeline:
Most recent: Clinical Trial Update: A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma [Phase 1]